Patents by Inventor Jack S. Remington
Jack S. Remington has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20030119053Abstract: The present invention relates to combinations or mixtures of antigens which may be used in the detection of IgM and/or IgG antibodies to Toxoplasma gondii as well as to the P35 antigen which may be used to distinguish acute from chronic Toxoplasmosis. Furthermore, the present invention also relates to methods of using these combinations of antigens, antibodies raised against these combinations of antigens or against the novel P29 antigen thereof, as well as kits and vaccines containing the antigens present in the combinations.Type: ApplicationFiled: December 1, 2000Publication date: June 26, 2003Inventors: Gregory T. Maine, Jeffrey C. Hunt, Susan Brojanac, Michael Jyh-Tsing Sheu, Linda E. Chovan, Joan D. Tyner, Lawrence V. Howard, Stephen F. Parmley, Jack S. Remington, Fausto Araujo, Yashuhiro Suzuki, Shuli Li
-
Patent number: 6221619Abstract: The present invention relates to combinations or mixtures of antigens which may be used in the detection of IgM and/or IgG antibodies to Toxoplasma gondii as well as to the P35 antigen which may be used to distinguish acute from chronic toxoplasmosis. Furthermore, the present invention also relates to methods of using these combinations of antigens, antibodies raised against these combinations of antigens or against the novel P29 antigen thereof, as well as kits and vaccines containing the antigens present in the combinations.Type: GrantFiled: April 30, 1999Date of Patent: April 24, 2001Assignee: Abbott LaboratoriesInventors: Gregory T. Maine, Jeffrey C. Hunt, Susan Brojanac, Michael Jyh-Tsing Sheu, Linda E. Chovan, Joan D. Tyner, Lawrence V. Howard, Stephen F. Parmley, Jack S. Remington, Fausto Araujo, Yashuhiro Suzuki, Shuli Li
-
Patent number: 5686575Abstract: Genetic material encoding the P28 peptide of Toxoplasma gondii has been isolated and characterized. This genetic material allows the production of peptides for use in diagnosis or immunization or can itself be directly used in hybridization assays.Type: GrantFiled: June 7, 1995Date of Patent: November 11, 1997Assignee: Palo Alto Medical FoundationInventors: Jeffrey B. Prince, Fausto G. De Araujo, Somesh D. Sharma, Jack S. Remington
-
Patent number: 5670496Abstract: A method of reducing the severity of toxoplasmosis resulting from infection of a patient with Toxoplasma gondii by administering to a patient in need of such treatment, either after infection or before exposure to infection, a therapeutically effective amount of a compound that is a spiropiperidyl derivative of rifamycin S, wherein the derivative comprises an imidazole ring that includes carbons at positions 3 and 4 of the rifamycin ring, the carbon at position 2 of the imidazole ring also being a ring carbon at position 4 of a piperidine ring system, thereby forming a spiropiperidyl ring system, the spiropiperidyl ring system optionally comprising a lower hydrocarbon substituent on the nitrogen of the piperidine.Type: GrantFiled: June 7, 1995Date of Patent: September 23, 1997Assignee: Palo Alto Medical FoundationInventors: Jack S. Remington, Fausto G. Araujo
-
Patent number: 5665542Abstract: Genetic material encoding the P28 peptide of Toxoplasma gondii has been isolated and characterized. This genetic material allows the production of peptides for use in diagnosis or immunization or can itself be directly used in hybridization assays.Type: GrantFiled: February 3, 1992Date of Patent: September 9, 1997Assignee: Research Institute of Palo Alto Medical FoundationInventors: Jeffrey B. Prince, Fausto G. De Araujo, Somesh D. Sharma, Jack S. Remington
-
Patent number: 5665707Abstract: A method of reducing the severity of toxoplasmosis resulting from infection of a patient with Toxoplasma gondii by administering to a patient in need of such treatment, either after infection or before exposure to infection, a therapeutically effective amount of a compound that is a spiropiperidyl derivative of rifamycin S, wherein the derivative comprises an imidazole ring that includes carbons at positions 3 and 4 of the rifamycin ring, the carbon at position 2 of the imidazole ring also being a ring carbon at position 4 of a piperidine ring system, thereby forming a spiropiperidyl ring system, the spiropiperidyl ring system optionally comprising a lower hydrocarbon substituent on the nitrogen of the piperidine.Type: GrantFiled: June 7, 1995Date of Patent: September 9, 1997Assignee: Palo Alto Medical FoundationInventors: Jack S. Remington, Fausto G. Araujo
-
Patent number: 5650405Abstract: A method of reducing the severity of toxoplasmosis resulting from infection of a patient with Toxoplasma gondii by administering to a patient in need of such treatment, either after infection or before exposure to infection, a therapeutically effective amount of a compound that is a spiropiperidyl derivative of rifamycin S, wherein the derivative comprises an imidazole ring that includes carbons at positions 3 and 4 of the rifamycin ring, the carbon at position 2 of the imidazole ring also being a ring carbon at position 4 of a piperidine ring system, thereby forming a spiropiperidyl ring system, the spiropiperidyl ring system optionally comprising a lower hydrocarbon substituent on the nitrogen of the piperidine.Type: GrantFiled: June 7, 1995Date of Patent: July 22, 1997Assignee: Palo Alto Medical FoundationInventors: Jack S. Remington, Fausto G. Araujo
-
Patent number: 5648345Abstract: A method of reducing the severity of toxoplasmosis resulring from infection of a patient with Toxoplasma gondii by administering to a patient in need of such treatment, either after infection or before exposure to infection, a therapeutically effective amount of a compound that is a spiropiperidyl derivative of rifamycin S, wherein the derivative comprises an imidazole ring that includes carbons at positions 3 and 4 of the rifamycin ring, the carbon at position 2 of the imidazole ring also being a ring carbon at position 4 of a piperidine ring system, thereby forming a spiropiperidyl ring system, the spiropiperidyl ring system optionally comprising a lower hydrocarbon substituent on the nitrogen of the piperidine.Type: GrantFiled: June 7, 1995Date of Patent: July 15, 1997Assignee: Palo Alto Medical FoundationInventors: Jack S. Remington, Fausto G. Araujo
-
Patent number: 5641769Abstract: A method of reducing the severity of toxoplasmosis resulting from infection of a patient with Toxoplasma gondii by administering to a patient in need of such treatment, either after infection or before exposure to infection, a therapeutically effective amount of a compound that is a spiropiperidyl derivative of rifamycin S, wherein the derivative comprises an imidazole ring that includes carbons at positions 3 and 4 of the rifamycin ring, the carbon at position 2 of the imidazole ring also being a ring carbon at position 4 of a piperidine ting system, thereby forming a spiropiperidyl ring system, the spiropiperidyl ring system optionally comprising a lower hydrocarbon substituent on the nitrogen of the piperidine.Type: GrantFiled: June 7, 1995Date of Patent: June 24, 1997Assignee: Palo Alto Medical FoundationInventors: Jack S. Remington, Fausto G. Araujo
-
Patent number: 5633139Abstract: Genetic material encoding the P28 peptide of Toxoplasma gondii has been isolated and characterized. This genetic material allows the production of peptides for use in diagnosis or immunization or can itself be directly used in hybridization assays.Type: GrantFiled: June 7, 1995Date of Patent: May 27, 1997Assignee: Research Institute of Palo Alto Medical FoundationInventors: Jeffrey B. Prince, Fausto G. De Araujo, Somesh D. Sharma, Jack S. Remington
-
Patent number: 5529994Abstract: A method of reducing the severity of toxoplasmosis resulting from infection of a patient with Toxoplasma gondii by administering to a patient in need of such treatment, either after infection or before exposure to infection, a therapeutically effective amount of a compound that is a spiropiperidyl derivative of rifamycin S, wherein the derivative comprises an imidazole ring that includes carbons at positions 3 and 4 of the rifamycin ring, the carbon at position 2 of the imidazole ring also being a ring carbon at position 4 of a piperidine ring system, thereby forming a spiropiperidyl ring system, the spiropiperidyl ring system optionally comprising a lower hydrocarbon substituent on the nitrogen of the piperidine.Type: GrantFiled: February 28, 1994Date of Patent: June 25, 1996Assignee: Palo Alto Medical FoundationInventors: Jack S. Remington, Fausto G. Araujo
-
Patent number: 5472844Abstract: Genetic material encoding the P22 peptide of Toxoplasma gondii has been isolated and characterized. This genetic material allows the production of peptides for use in diagnosis or immunization or can itself be directly used in hybridization assays.Type: GrantFiled: October 25, 1994Date of Patent: December 5, 1995Assignee: Research Institute of Palo Alto Medical FoundationInventors: Fausto G. De Araujo, Jeffrey B. Prince, Jack S. Remington
-
Patent number: 5215917Abstract: Genetic material encoding the P22 peptide of Toxoplasma gondii has been isolated and characterized. This genetic material allows the production of peptides for use in diagnosis or immunization or can itself be directly used in hybridization assays.Type: GrantFiled: November 3, 1989Date of Patent: June 1, 1993Assignee: Research Institute of Palo Alto Medical FoundationInventors: Fausto G. De Araujo, Jeffrey B. Prince, Jack S. Remington
-
Patent number: 4963531Abstract: A method of use of azithromycin or derivatives of azithromycin in the treatment of infection caused by Toxoplasma gondii in mammals is disclosed.Type: GrantFiled: August 16, 1988Date of Patent: October 16, 1990Assignee: Pfizer Inc.Inventor: Jack S. Remington
-
Patent number: 4877726Abstract: A method of detecting Toxoplasma infection and distinguishing acute infection from chronic infection is provided, comprising the steps of combining a sample suspected of containing antibodies to Toxoplasma antigens with a acute-phase-specific antigen reactive with an antibody specific for an acetone-treated Toxoplasma antigen under conditions favorable for formation of antigen-antibody complex, and detecting formation of the complex.Type: GrantFiled: March 2, 1988Date of Patent: October 31, 1989Assignee: Research Institute of Palo Alto Medical FoundationInventors: Yasuhiro Suzuki, Jack S. Remington, Georges Desmonts, Philippe Thulliez
-
Patent number: 4612281Abstract: An immunoassay for detecting disease associated Ig, such as IgM associated with acute forms of Toxoplasma gondii infection. Wells of microtiter plates are first coated with an antibody against the Ig to be detected and the test sample, e.g. serum, is then added and incubated. After removal of non-adsorbed materials from the wells, an insoluble visible form of the cognate antigen to the Ig, such as antigen fixed to latex particles, is added. If no such Ig is present in the sample, the antigen will appear as a smooth button on the bottom of the well; whereas if such Ig is present in significant quantity, the antigen will be captured by adsorbed antiIg-Ig complexes and distributed on the wall of the well according to the distribution of the antiIg-Ig complex thereon.Type: GrantFiled: November 5, 1982Date of Patent: September 16, 1986Assignee: Palo Alto Medical Foundation Research InstituteInventors: Georges Desmonts, Jack S. Remington
-
Patent number: 4361647Abstract: An improved sandwich immunoassay for Toxoplasma gondii antigens associated with acute forms of Toxoplasma infection is disclosed. The assay employs either an F(ab').sub.2 fragment of IgG which reacts specifically with such antigens or a monoclonal antibody for such antigens as the substrate layer in the sandwich. The assay is sensitive and, unlike prior sandwich assays for the antigen, is not affected significantly by cross-reactions with rheumatoid factor.Type: GrantFiled: May 22, 1980Date of Patent: November 30, 1982Assignee: Palo Alto Medical Research FoundationInventors: Jack S. Remington, Fausto G. Araujo